What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Surgery
His primary areas of study are Surgery, Internal medicine, Carcinoma, Cancer and Radiation therapy.
His Surgery research includes elements of Respiratory disease, Lung and Pneumonectomy.
Stephen G. Swisher has included themes like Gastroenterology, Oncology and Histopathology in his Internal medicine study.
His study in Carcinoma is interdisciplinary in nature, drawing from both Neoadjuvant therapy, Lung cancer, Chemotherapy and Antigen.
His Cancer research includes themes of Prospective cohort study, Esophageal disease and Urology.
His work carried out in the field of Radiation therapy brings together such families of science as Standard treatment, Univariate analysis and Esophageal cancer.
His most cited work include:
- Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing (622 citations)
- Adenovirus-Mediated p53 Gene Transfer in Advanced Non-Small-Cell Lung Cancer (446 citations)
- Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study (432 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Internal medicine, Lung cancer, Surgery, Cancer and Oncology.
His Internal medicine study frequently links to related topics such as Gastroenterology.
His biological study spans a wide range of topics, including Cancer research and Immune system, Immunotherapy.
His research investigates the link between Surgery and topics such as Esophageal cancer that cross with problems in Chemoradiotherapy, Radiology and Univariate analysis.
Stephen G. Swisher has researched Cancer in several fields, including Esophageal disease and Pathology.
As a part of the same scientific family, Stephen G. Swisher mostly works in the field of Oncology, focusing on Proportional hazards model and, on occasion, Primary tumor.
He most often published in these fields:
- Internal medicine (39.42%)
- Lung cancer (33.65%)
- Surgery (31.49%)
What were the highlights of his more recent work (between 2018-2021)?
- Lung cancer (33.65%)
- Internal medicine (39.42%)
- Oncology (28.85%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Lung cancer, Internal medicine, Oncology, Cancer research and Chemotherapy.
His Lung cancer research is multidisciplinary, relying on both Neoadjuvant therapy, Perioperative, Surgery and Lung.
His Surgery study incorporates themes from Esophagectomy and Esophageal cancer.
Stephen G. Swisher works mostly in the field of Internal medicine, limiting it down to concerns involving Gastroenterology and, occasionally, Adenocarcinoma.
His Oncology research incorporates elements of Major Pathologic Response, Targeted therapy, Proportional hazards model, Stage and Immunotherapy.
His studies in Cancer research integrate themes in fields like Immune checkpoint, Cancer cell, Cancer and T cell, Immune system.
Between 2018 and 2021, his most popular works were:
- Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. (286 citations)
- Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study. (62 citations)
- Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. (50 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Surgery
His scientific interests lie mostly in Internal medicine, Oncology, Lung cancer, Cancer research and Immunotherapy.
He interconnects Targeted therapy, Disease, Immune checkpoint inhibitors and PD-L1 in the investigation of issues within Oncology.
His Lung cancer study combines topics in areas such as Neoadjuvant therapy, Clinical trial, Chemotherapy, Carcinoma and Radiation therapy.
His Cancer research research is multidisciplinary, incorporating elements of Cell, Gene expression, Circulating tumor cell, Cancer cell and Immune system.
His research integrates issues of T cell, Survival analysis, Cisplatin and Antigen in his study of Immunotherapy.
His research combines Cancer and Surgery.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
